Roche announced that it has signed a global business partnership agreement with Sysmex, renewing a long-standing arrangement allowing Roche to distribute Sysmex hematology testing products, including instruments and reagents, according to a press release from Roche.
Roche also said the companies plan to work together “to utilize their respective IT platforms to improve the customer’s experience in the short to mid-term, with a longer-term ambition to use the IT systems to lead to improved clinical decision making.”
The agreement will run until the end of 2030.
“Roche is committed to supporting improvements in hematology testing, which helps patients with the diagnosis and management of blood diseases, as diverse as anemia and leukemia,” said Thomas Schinecker, CEO Roche Diagnostics. “Extending our longstanding partnership with Sysmex underscores our unique synergy and our objective to offer our customers high-quality hematology solutions to improve the testing efficiency in central laboratories in hospitals and commercial laboratories, ultimately benefiting the millions of patients living with blood disorders.”
Roche and Sysmex first signed a distribution agreement In 1999.In 2018, Roche and Sysmex entered into a non-exclusive collaboration agreement to offer total laboratory solutions (TLS), allowing customers to purchase products for clinical chemistry, immunochemistry, and hematology testing from one vendor.
